Kangstem Biotech Co., Ltd. Stock price

Equities

A217730

KR7217730001

Biotechnology & Medical Research

End-of-day quote Korea S.E. 23:00:00 20/02/2024 GMT 5-day change 1st Jan Change
1,938 KRW +0.52% Intraday chart for Kangstem Biotech Co., Ltd. -0.87% -19.08%

Financials

Sales 2021 12.4B 9.3M 737M Sales 2022 16.3B 12.23M 969M Capitalization 110B 82.37M 6.53B
Net income 2021 -21.35B -16.01M -1.27B Net income 2022 -20.24B -15.18M -1.2B EV / Sales 2021 6.57 x
Net cash position 2021 42.54B 31.91M 2.53B Net cash position 2022 23.31B 17.48M 1.39B EV / Sales 2022 5.31 x
P/E ratio 2021
-4.27 x
P/E ratio 2022
-5.43 x
Employees 115
Yield 2021 *
-
Yield 2022
-
Free-Float 94.92%
More Fundamentals * Assessed data
Dynamic Chart
Kangstem Biotech Co., Ltd.(KOSDAQ:A217730) dropped from S&P Global BMI Index CI
Kang Stem Biotech to Raise 35.1 Billion Won via Shares Issuance; Shares Plunge 30% MT
Kangstem Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kang Stem Biotech Co., Ltd. announced that it has received KRW 47.99962221 billion in funding from a group of investors CI
Kang Stem Biotech Co., Ltd. announced that it expects to receive KRW 47.99962221 billion in funding from a group of investors CI
Kang Stem Biotech Co., Ltd. cancelled the acquisition of 60% stake in Croen Inc. CI
Kang Stem Biotech Co., Ltd. announced that it has received KRW 1.40 billion in funding CI
Kang Stem Biotech Co., Ltd. agreed to acquire a 60% stake in Croen Inc. for KRW 2.7 billion. CI
Kang Stem Biotech Co., Ltd. announced that it expects to receive KRW 1.40 billion in funding CI
Kang Stem Biotech Co., Ltd. announced that it has received KRW 30 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, LIG Investment & Securities Co., Ltd., Investment Arm, and other investors CI
Kang Stem Biotech Co., Ltd. announced that it expects to receive KRW 30 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, LIG Investment & Securities Co., Ltd., Investment Arm, and other investors CI
ORIG3N, Inc and Kangstem Biotech Announce Collaboration to Study Neural Stem Cells CI
Lutronic Corporation cancelled the sale of 4.11% stake in Kang Stem Biotech Co., Ltd. CI
Kang Stem Biotech Co., Ltd.(KOSDAQ:A217730) added to S&P Global BMI Index CI
Kang Stem Biotech Co., Ltd. has completed an IPO in the amount of KRW 12.00 billion. CI
More news
1 day+0.52%
1 week-0.87%
Current month-1.87%
1 month-1.42%
3 months+44.09%
6 months+0.73%
Current year-19.08%
More quotes
1 week
1 904.00
Extreme 1904
2 000.00
1 month
1 828.00
Extreme 1828
2 140.00
Current year
1 828.00
Extreme 1828
2 540.00
1 year
1 166.00
Extreme 1166
3 490.00
3 years
1 166.00
Extreme 1166
7 400.00
5 years
1 166.00
Extreme 1166
23 600.00
10 years
1 166.00
Extreme 1166
24 400.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 -
Chief Tech/Sci/R&D Officer 43 -
Comptroller/Controller/Auditor 64 -
Members of the board TitleAgeSince
Director/Board Member 68 -
Director/Board Member 63 -
Director/Board Member 71 -
More insiders
Date Price Change Volume
20/02/24 1,938 +0.52% 116 643
20/02/24 1,928 -0.16% 55,105
19/02/24 1,931 -0.62% 69,633
16/02/24 1,943 +0.05% 77,628
15/02/24 1,942 +0.10% 82,631

End-of-day quote Korea S.E., February 20, 2024

More quotes
Kang Stem Biotech Co., LTD is a Korea-based company mainly engaged in the development of pharmaceutical products. The Company's product portfolio consists of stem cell therapy products including Furestem-AD which used for treating atopic dermatitis, Furestem-RA which used for treating rheumatoid arthritis, Furestem-CD which used for treating crohn's disease, stem cell conditioned medias which used as raw materials of cosmetics including umbilical cord blood-derived stem cell conditioned medias (USC-CMs) and others and stem cell culture medias including KSB-3 Complete Kit and others. The Company distributes its products within domestic market and to overseas markets.
More about the company
  1. Stock
  2. Equities
  3. Stock Kangstem Biotech Co., Ltd. - Korea S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer